ClinicaliQ Trial Snapshot
- Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease — Recruiting • Phase III • Cardiology / Cardiovascular • NCT07223593.
- What is being tested: Orforglipron, a once-daily treatment, is being evaluated for its efficacy and safety in managing Fontaine II peripheral arterial disease (symptomatic claudication with reproducible symptoms on exercise).
- Patient eligibility overview: The trial enrolls participants with confirmed Fontaine II PAD, which represents the symptomatic claudication stage of peripheral artery disease; specific inclusion/exclusion criteria would determine cardiovascular risk profile and disease severity requirements.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the effect and safety of orforglipron once daily in participants with Fontaine II peripheral arterial disease (PAD). Participation in the study will last about 58 weeks.
Eligibility Snapshot
- : * Have symptomatic PAD with intermittent claudication of Fontaine Stage II * Have an Ankle Brachial Index (ABI) of 0.9 or less
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.